Danish biotechnology company Teitur Trophics announced on September 10, 2026, that its lead neuroprotective peptide TT-P34 was safe and well tolerated across a randomized, double-blind, placebo-controlled Phase I clinical trial, with pharmacokinetic data confirming the drug successfully reaches the human brain and central nervous system. According to the company, the compound targets underlying cellular mechanisms in Parkinson’s disease by simultaneously addressing mitochondrial and lysosomal dysfunction.
Phase I Trial Design and Safety Results for TT-P34
The Phase I study (2025-521357-17-00) was conducted at the Centre for Human Drug Research in Leiden, the Netherlands, as detailed by the company. The trial enrolled 55 healthy volunteers—split into 31 participants in a single ascending dose phase and 24 in a multiple ascending dose phase—alongside a separate cohort of 12 patients with early-stage Parkinson’s disease. Once-weekly subcutaneous administration of TT-P34 proved safe and well tolerated at every tested dose, with no dose-limiting findings reported.
In the patient cohort, the peptide was well tolerated when administered alongside levodopa, the standard-of-care medication for Parkinson’s disease. Andreas Borta, chief medical officer of Teitur Trophics, stated that the data shows the therapy has an excellent safety profile, enters the brain and central nervous system as expected, and demonstrates strong pharmacokinetics. Simon Mølgaard, co-founder and CEO of Teitur Trophics, explained to BioXconomy that measuring drug levels in the fluid around the brain and spinal cord confirmed the amounts reached the range believed necessary to exert a real effect on the disease.
Dual Mechanism Targeting Mitochondria and lysosomes
TT-P34 is a cyclic peptide originating from the neuro-regulatory SorCS2 transmembrane receptor, engineered to reactivate the transcription factor CREB. According to Teitur Trophics, this action restores mitochondrial energy production and repairs lysosomal waste clearance systems. Mølgaard noted that mitochondria failing to produce enough energy and lysosomes stopping waste clearance together drive disease progression, whereas most treatments currently in development tackle only one of these issues.
Biomarker data from cerebrospinal fluid samples gathered during the trial indicated active engagement of the lysosomal pathway. Over the 50-day study period, the majority of Parkinson’s patients receiving TT-P34 showed coordinated changes across multiple recycling-related proteins. Borta noted that these biomarker data provide an encouraging early sign that the molecule interacts with cellular machinery responsible for clearing toxic protein aggregates.
Navigating the High Bar for Parkinson’s Disease Modification
The pursuit of disease-modifying therapies in neurology faces a high failure rate, setting a challenging backdrop for new candidates. Ambroxol targets the lysosomal enzyme GCase in Phase 3 studies, while Roche’s anti-alpha-synuclein antibody prasinezumab advanced to Phase 3 in 2026 despite missing its primary endpoint in a Phase 2b trial in December 2024. Conversely, Biogen and Denali discontinued development of their LRRK2 inhibitor BIIB122 for idiopathic Parkinson’s disease in May 2026 after it failed to slow progression in a Phase 2b study.
Against these industry hurdles, Teitur Trophics is positioning TT-P34 for broader neurodegenerative applications, including frontotemporal dementia and Huntington’s disease, leveraging its mitochondrial mechanism. While the Phase I trial establishes safety and central nervous system penetration rather than clinical efficacy, the company plans to initiate a Phase II trial in 2027 to evaluate whether the peptide can actively slow disease progression.
Frequently Asked Questions
What is TT-P34?
TT-P34 is a first-in-class neuroprotective cyclic peptide developed by Teitur Trophics to target mitochondrial and lysosomal dysfunction in neurodegenerative conditions like Parkinson’s disease.
What did the Phase I trial discover?
According to clinical data released by Teitur Trophics, the trial established a clean safety and tolerability profile across 67 participants and confirmed that the peptide successfully penetrates the central nervous system following once-weekly subcutaneous dosing.
When will Phase II clinical trials begin?
Teitur Trophics has scheduled the start of its Phase II clinical trial for TT-P34 in 2027 to assess disease-modifying benefits in Parkinson’s patients.
Interested in staying updated on clinical trial advancements in neurodegeneration? Subscribe to our newsletter or explore our latest reporting on biotechnology breakthroughs.